(1.02%) 5 099.96 points
(0.40%) 38 240 points
(2.03%) 15 928 points
(-0.85%) $83.14
(-1.16%) $1.619
(-0.44%) $2 336.80
(0.78%) $27.47
(0.48%) $926.50
(-0.17%) $0.933
(-0.16%) $11.01
(-0.25%) $0.798
(0.00%) $92.17
0.14% $ 273.67
Live Chart Being Loaded With Signals
CSL Limited researches, develops, manufactures, markets, and distributes biopharmaceutical and allied products in Australia, the United States, Germany, the United Kingdom, Switzerland, China, and internationally...
Stats | |
---|---|
Dzisiejszy wolumen | 107 103 |
Średni wolumen | 725 457 |
Kapitalizacja rynkowa | 132.25B |
EPS | $0 ( 2024-02-13 ) |
Last Dividend | $1.621 ( 2023-03-09 ) |
Next Dividend | $0 ( N/A ) |
P/E | 34.91 |
ATR14 | $0.100 (0.04%) |
Wolumen Korelacja
CSL Ltd Korelacja
10 Najbardziej pozytywne korelacje |
---|
10 Najbardziej negatywne korelacje |
---|
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
CSL Ltd Korelacja - Waluta/Towar
CSL Ltd Finanse
Annual | 2023 |
Przychody: | $19.59B |
Zysk brutto: | $9.47B (48.33 %) |
EPS: | $6.92 |
FY | 2023 |
Przychody: | $19.59B |
Zysk brutto: | $9.47B (48.33 %) |
EPS: | $6.92 |
FY | 2022 |
Przychody: | $14.47B |
Zysk brutto: | $7.68B (53.05 %) |
EPS: | $6.63 |
FY | 2021 |
Przychody: | $10.27B |
Zysk brutto: | $5.80B (56.49 %) |
EPS: | $5.22 |
Financial Reports:
No articles found.
CSL Ltd Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
$1.758 (N/A) |
$0 (N/A) |
$1.621 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
Very Unsafe
High risk of being cut
Unsafe
Heightened risk of being cut
Borderline
Moderate risk of being cut
Safe
Unlikely to be cut
Very Safe
Very unlikely to be cut
First Dividend | $0.0167 | 1994-11-08 |
Last Dividend | $1.621 | 2023-03-09 |
Next Dividend | $0 | N/A |
Payout Date | 0000-00-00 | |
Next Payout Date | N/A | |
# dividends | 59 | -- |
Total Paid Out | $28.07 | -- |
Avg. Dividend % Per Year | 0.00% | -- |
Score | 4.48 | -- |
Div. Sustainability Score | 10.00 | |
Div.Growth Potential Score | 7.26 | |
Div. Directional Score | 9.64 | -- |
Year | Amount | Yield |
---|
The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. Furthermore, its high Dividend Growth Potential Score (DGPS) signals potential dividend growth. In summary, the company provides a promising overall dividend outlook, balancing both sustainability and growth potential.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
OMH.AX | Ex Dividend Junior | 2023-05-04 | Sporadic | 0 | 0.00% | |
AFG.AX | Ex Dividend Junior | 2023-09-04 | Semi-Annually | 0 | 0.00% | |
GDG.AX | Ex Dividend Junior | 2023-09-08 | Semi-Annually | 0 | 0.00% | |
QBE.AX | Ex Dividend Knight | 2023-08-17 | Annually | 0 | 0.00% | |
BBN.AX | Ex Dividend Knight | 2023-08-24 | Semi-Annually | 0 | 0.00% | |
JBH.AX | Ex Dividend Knight | 2023-08-24 | Semi-Annually | 0 | 0.00% | |
SIG.AX | Ex Dividend Knight | 2023-09-25 | Annually | 0 | 0.00% | |
CIA.AX | Ex Dividend Knight | 2023-06-13 | Semi-Annually | 0 | 0.00% | |
MMS.AX | Ex Dividend Junior | 2023-09-07 | Annually | 0 | 0.00% | |
URF.AX | No Dividend Player | 2023-06-29 | Annually | 0 | 0.00% |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | 0.180 | 1.500 | 6.41 | 9.61 | [0 - 0.5] |
returnOnAssetsTTM | 0.0696 | 1.200 | 7.68 | 9.21 | [0 - 0.3] |
returnOnEquityTTM | 0.156 | 1.500 | 9.38 | 10.00 | [0.1 - 1] |
payoutRatioTTM | 0.450 | -1.000 | 5.50 | -5.50 | [0 - 1] |
currentRatioTTM | 2.15 | 0.800 | 4.25 | 3.40 | [1 - 3] |
quickRatioTTM | 0.971 | 0.800 | 9.00 | 7.20 | [0.8 - 2.5] |
cashRatioTTM | 0.216 | 1.500 | 9.91 | 10.00 | [0.2 - 2] |
debtRatioTTM | 0.282 | -1.500 | 5.30 | -7.95 | [0 - 0.6] |
interestCoverageTTM | 6.97 | 1.000 | 8.53 | 8.53 | [3 - 30] |
operatingCashFlowPerShareTTM | 8.34 | 2.00 | 7.22 | 10.00 | [0 - 30] |
freeCashFlowPerShareTTM | 3.59 | 2.00 | 8.21 | 10.00 | [0 - 20] |
debtEquityRatioTTM | 0.612 | -1.500 | 7.55 | -10.00 | [0 - 2.5] |
grossProfitMarginTTM | 0.484 | 1.000 | 5.26 | 5.26 | [0.2 - 0.8] |
operatingProfitMarginTTM | 0.244 | 1.000 | 7.12 | 7.12 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | 0.261 | 1.000 | 9.66 | 9.66 | [0.2 - 2] |
assetTurnoverTTM | 0.388 | 0.800 | -0.748 | -0.599 | [0.5 - 2] |
Total Score | 12.02 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | 34.66 | 1.000 | 6.60 | 0 | [1 - 100] |
returnOnEquityTTM | 0.156 | 2.50 | 9.60 | 10.00 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | 3.59 | 2.00 | 8.80 | 10.00 | [0 - 30] |
dividendYielPercentageTTM | 1.393 | 1.500 | 10.00 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | 8.34 | 2.00 | 7.22 | 10.00 | [0 - 30] |
payoutRatioTTM | 0.450 | 1.500 | 5.50 | -5.50 | [0 - 1] |
pegRatioTTM | 7.92 | 1.500 | 10.00 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | 0.190 | 1.000 | 7.75 | 0 | [0.1 - 0.5] |
Total Score | 7.26 |
CSL Ltd
CSL Limited researches, develops, manufactures, markets, and distributes biopharmaceutical and allied products in Australia, the United States, Germany, the United Kingdom, Switzerland, China, and internationally. The company operates through two segments, CSL Behring and CSL Seqirus. The CSL Behring segment offers plasma therapies, such as plasma products and recombinants. This segment also conducts research on plasma and non-plasma therapies; and receives license and royalty from the commercialization of intellectual property. The CSL Seqirus segment manufactures and distributes non-plasma biotherapeutic products; and develops influenza related products. CSL Limited was founded in 1916 and is headquartered in Parkville, Australia.
O Sygnały na żywo
Prezentowane na tej stronie sygnały na żywo pomagają określić, kiedy KUPIĆ lub SPRZEDAĆ BRAK DANYCH. Sygnały mogą mieć opóźnienie wynoszące nawet 1 minutę; jak wszystkie sygnały rynkowe, istnieje ryzyko błędu lub pomyłki.
Sygnały transakcyjne na żywo nie są ostateczne i getagraph.com nie ponosi odpowiedzialności za żadne działania podjęte na podstawie tych sygnałów, jak opisano w Warunkach Użytkowania. Sygnały opierają się na szerokim zakresie wskaźników analizy technicznej